Is the Addition of Chemotherapy to Adjuvant Radiation in Merkel Cell Cancer Beneficial? Real-World Data with Long-Term Follow-Up
While the multivariate analysis did not indicate a survival advantage to adding chemotherapy to radiation, the comparable survival outcomes despite significantly more advanced disease in the chemoradiation group suggest a possible benefit in high-risk patients. Our results indicate the need for prospective studies with larger, stage-matched cohorts to definitively establish the role of adjuvant chemotherapy in high-risk resectable MCC.
Authors
- T. N. Tairov
- Shlomit Fenig
- Eyal Fenig (ORCID: https://orcid.org/0000-0003-1338-3189)
- Ronen Brenner (ORCID: https://orcid.org/0000-0002-9901-9654)
- Ilia Berezhnov
- Tomer Ziv‐Baran (ORCID: https://orcid.org/0000-0002-2589-8473)
- Alexander Yakobson
- Anna Ievko
- Ina Sarel
- Walid Shalata (ORCID: https://orcid.org/0000-0002-7570-4550)
- Hanna T. Frumin Edri
- Sofiia Turaieva
Institutions
- Ben-Gurion University of the Negev (IL)
- Tel Aviv University (IL)
- Kaplan Medical Center (IL)
- Rabin Medical Center (IL)
- Soroka Medical Center (IL)
- Wolfson Medical Center (IL)
- Alzheimer's Association of Israel (IL)
Publication Details
- Journal
- Cancers
- Published
- 2025-03-11
- DOI
- https://doi.org/10.3390/cancers17060945
- Citations
- 1
- Primary Topic
- Polyomavirus and related diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.05